Research Article
Synthesis, Antimicrobial, and Anticancer Activities of Novel Nitrofuran Derivatives
Table 1
Biological evaluation (MICs, μg/mL) of the synthesized derivatives against selected microorganisms.
| | | MIC (μg/mL) | | Species/compound | 2 | 3 | 4 | 5 | 6 | 7 |
| | Gram-positive bacteria | Staphylococcus aureus (MRSA) | >32 | >32 | >32 | 8 (Dmax 95.5%) | 1 (Dmax 98.5%) | 32 (Dmax 93.7%) |
| | Gram-negative bacteria | Escherichia coli | >32 | >32 | >32 | 32 (Dmax 97.6%) | 32 (Dmax 98.9%) | >32 | | Pseudomonas aeruginosa | >32 | >32 | >32 | >32 | >32 | >32 | | Acinetobacter baumannii | >32 | >32 | >32 | 32 (Dmax 99.9%) | 32 (Dmax 89.9%) | 32 (Dmax 85.3%) | | Klebsiella pneumoniae (MDR KP) | >32 | >32 | >32.0 | >32 | 32 (Dmax 96.1%) | >32 |
| | Fungi | Candida albicans | >32 | >32 | >32.0 | >32 | >32 | >32 | | Cryptococcus neoformans | >32 | >32 | >32.0 | >32 | >32 | >32 |
|
|
∗p < 0.05.
|
